Biotechnology
GenFleet Starts Phase Ib/II Trial of GFH009 (Highly Selective CDK9 Inhibitor) Treating Patients with Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL)
SHANGHAI, Oct. 10, 2023 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the first subject was dosed in a phase Ib/II trial of GFH009 (a highly selective CDK9 inhibitor) treating relapsed/r...
2023-10-10 19:00
1486
Scorpion Therapeutics and Pierre Fabre Laboratories Announce First Patient Dosed in Phase 1/2 Clinical Trial of STX-721, a Mutant-Selective EGFR Exon 20 Inhibitor for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer
-- STX-721 is characterized by high selectivity and a potentially best-in-class profile -- -- Scorpion's second program to enter clinical development this year -- -- One of two EGFR programs being developed with Pierre Fabre Laboratories -- BOSTON and CASTRES, France, Oct. 10, 2023 /PRNewswire/...
2023-10-10 18:00
1575
GC Biopharma Signs Power Purchase Agreement with SK E&S
YONGIN, South Korea, Oct. 10, 2023 /PRNewswire/ -- GC Biopharma Corp. announced on today that it has signed Power Purchase Agreement (PPA) with SK E&S Co., Ltd onOctober 5th at its Ochang Plant. PPA is an electricity trading contract signed directly between a power generator and a customer c...
2023-10-10 14:20
1472
CanariaBio and Hikma announce the signing of distribution and license agreement for oregovomab in MENA Region
SEOUL, South Korea, Oct. 10, 2023 /PRNewswire/ -- CanariaBio Inc. and Hikma MENA FZE, part of Hikma Pharmaceuticals PLC (Hikma), today announced the signing of distribution and license agreement for oregovomab in theMiddle East andNorth Africa (MENA) region. "We are thrilled to partner with Hi...
2023-10-10 12:00
1620
TransThera announces two oral presentations of tinengotinib clinical data at 2023 ESMO and SABCS annual meetings
NANJING, China, Oct. 9, 2023 /PRNewswire/ -- TransThera Sciences (Nanjing) Inc., a clinical-stage biopharmaceutical company focused on inventing differentiated drugs for global patients, today announces to deliver two oral presentations of tinengotinib clinical data in cholangiocarcinoma (CCA) at...
2023-10-09 21:00
1576
bioSeedin Biopharma Developer Innovation Conference Held to Accelerate Global Pharmaceutical Innovation and Collaboration
BOSTON, Oct. 9, 2023 /PRNewswire/ -- Recently, the fifth Biopharma Developer Innovation Conference (BDIC) & 2023 bioSeedin Annual Meeting was successfully held inShanghai, China. This conference was hosted by bioSeedin and co-organized by ACROBiosystems (SZ.301080) to promote technical exchanges ...
2023-10-09 20:00
1572
Kexing Biopharm Holds China-MENA & South Asia Pharmaceutical Cooperation High-end Forum, Aiming at Foreign Emerging Markets
SHENZHEN, China, Oct. 9, 2023 /PRNewswire/ -- The 2023 China-MENA & South Asia Pharmaceutical Cooperation High-end Forum and Kexing Biopharm's Series of Globalization Activities were successfully held recently. MENA and South Asia are recognized as pivotal regions for Kexing Biopharm's overseas ...
2023-10-09 19:09
1751
AACR OVARIAN CANCER CONFERENCE PRESENTATION
HIGHLIGHTS * Data from preclinical studies in ovarian cancer presented at premier international conference inBoston, USA. * Results indicate that Amplia's proprietary FAK inhibitor narmafotinib (AMP945) performs better than standard-of-care in models of chemotherapy-resistant high-grade ser...
2023-10-09 15:18
1373
Innovent Announces First Patient Dosed in the Phase 3 Clinical Study (STAR) of Efdamrofusp Alfa (IBI302), a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Neovascular Age-related Macular Degeneration
ROCKVILLE, Md. and SUZHOU, China, Oct. 9, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and...
2023-10-09 08:00
5928
CANbridge Announces Marketing Approval of CAN108 (/LIVMARLI®) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (ALGS)
* LIVMARLI is the First and Only Treatment Approved in Taiwan for Cholestatic Pruritus in ALGS * LIVMARLI is approved for Cholestatic Pruritus in ALGS in the US, Canada, Europe, Mainland China, and other regions globally BEIJING and BURLINGTON, Mass. ,Oct. 8, 2023 /PRNewswire/ -- CANbridge Pha...
2023-10-09 08:00
1543
Gemdale Viseen Life Science Theme Industrial Park Strategy Officially Released
In recent years, basic research in life science has been developing rapidly, and competition in the industry has been intensifying. How is the development of the global life science industry heading under this market environment? How to build a better life science industry ecosystem? What kind of...
2023-10-06 11:57
2575
FDA Grants Orphan Drug Designation to GC Biopharma's Drug Candidate for Thrombotic Thrombocytopenic Purpura
YONGIN, South Korea, Oct. 5, 2023 /PRNewswire/ -- GC Biopharma Corp. announced today that GC1126A, its drug candidate for Thrombotic Thrombocytopenic Purpura (TTP), received an Orphan Drug Designation onSeptember 27 from the U.S. Food and Drug Administration (FDA). When designated as an orphan...
2023-10-06 08:12
2430
FII 7th EDITION UNITES GLOBAL LEADERS TO TACKLE HUMANITY'S GREATEST CHALLENGES
RIYADH, Saudi Arabia, Oct. 5, 2023 /PRNewswire/ -- The 7th Edition of the Future Investment Initiative (FII), slated to take place fromOctober 24th to 26th, 2023, in Riyadh, will convene an exceptional gathering of world leaders, industry titans, financiers, innovators, and policymakers. Themed "...
2023-10-05 20:08
3832
ProfoundBio to Participate in the Bank of America 2023 Healthcare Trailblazers Private Company Conference
SEATTLE, Oct. 5, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage biotechnology company focused on the development of novel antibody-drug conjugate therapeutics for cancer, announced that management will be participating in one-on-one meetings at Bank of America's Healthcare Trailblazers Priva...
2023-10-05 20:00
2403
Large-scale proteomics in population-based studies from UK and Iceland
REYKJAVIK, Iceland, Oct. 4, 2023 /PRNewswire/ -- In a paper released today, deCODE Genetics' scientists shared their findings from a plasma proteomics study performed using affinity-based methods. They analyzed the proteins in the context of diseases and diversity in the sequence of the genome an...
2023-10-04 23:00
2310
FUBON by Angel Yeast: Professional Yeast Solution for Sustainable Nutrition in Farming
YICHANG, China, Oct. 4, 2023 /PRNewswire/ -- On the occasion of World Animal
Day 2023 onOctober 4, animal nutrition brand FUBON by Angel Yeast
2023-10-04 20:00
2856
LOTTE BIOLOGICS Announces Land Purchase Agreement with Incheon Free Economic Zone Authority, Establishing New Foothold in Songdo
* Construction of a Bio Plant with a total production capacity of 360 kL at Songdo's Block KI20, Zone 11 by 2030 * Aims to secure capabilities of an international standard and expand client base by making the Bio Plant a key hub SEOUL, South Korea, Oct. 4, 2023 /PRNewswire/ -- LOTTE BIOLOGICS...
2023-10-04 18:14
1594
FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab (TST001) as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients
Osemitamab (TST001) on Track to Become a Global Therapy that Elevates the Current Standard of Care for HER2-Negative G/GEJ Adenocarcinoma PRINCETON, N.J. and SUZHOU, China, Oct. 3, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical co...
2023-10-04 08:00
1509
FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab (TST001) as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients
Osemitamab (TST001) on Track to Become a Global Therapy that Elevates the Current Standard of Care for HER2-Negative G/GEJ Adenocarcinoma PRINCETON, N.J. and SUZHOU, China, Oct. 4, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical co...
2023-10-04 08:00
2174
Menarini Silicon Biosystems announces new study results on use of CELLSEARCH® liquid biopsy for earlier detection of relapse and to help inform decisions on patient management in stage III Melanoma
Results of this MD Anderson study were recently published in Cancers and indicate the relevance of enumeration of Circulating Tumor Cells (CTCs) with the minimally invasive liquid biopsy-based CELLSEARCH® system to gain significantly earlier information, compared to standard imaging techniques, o...
2023-10-03 20:00
1936
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7433
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
6834
